About Carlsmed Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://carlsmed.com/
Frequently Asked Questions
What is the 52-week range for CARL?
The 52-week high is $17.23 and the 52-week low is $8.5.
What is the P/E ratio for CARL?
The P/E ratio data is currently unavailable.
What is the dividend yield for CARL?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -38.06%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -57.42%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.32.
Analyst Recommendation Trends
Wall Street analyst consensus for CARL over the last few months:
Latest CARL News
Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company’s common stock and 89,286 time-based restricted stock units (“RSUs”) to Richard Heppenstall, the Company’s newly-hired Chief Financial Officer, as a material inducement to his employment.
Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commercialization of the Company’s next generation technology platform, surgical UI/UX, and personalized spine surge
Carlsmed names new CFO
Former ZimVie CFO Richard Heppenstall fills the vacancy created by the departure of Leo Greenstein, who is leaving Carlsmed to pursue other professional interests.
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
Company Reaffirms Fiscal Year 2026 GuidanceCARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately. Mr. Heppenstall succeeds Leo Greenstein, who has served as CFO since 2023 and will be leaving Carlsmed to pursue other professional interests. “We
BTIG Reiterates Buy on Carlsmed, Maintains $23 Price Target
BTIG analyst Ryan Zimmerman reiterates Carlsmed (NASDAQ:CARL) with a Buy and maintains $23 price target.
Carlsmed Affirms FY2026 Sales Guidance of $74.000M-$78.000M vs $74.830M Est
Carlsmed (NASDAQ:CARL) affirms FY2026 sales outlook from $74.000 million-$78.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
Carlsmed Appoints Richard Heppenstall CFO, Succeeding Leo Greenstein; Co. Reiterates FY26 Revenue Range Of $74M - $78M
Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been
Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical
CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. (“DeGen”) in the United States District Court for the District of South Carolina Florence Division. The complaint asserts that DeGen is infringing eight of Carlsmed’s patents relating to its implants, methods and systems. Carlsmed is seeking i
Carlsmed, Inc. Announces Chief Operating Officer Appointment
CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Jeff Bertolini has been promoted to the role of Chief Operating Officer, effective immediately. Jeff joined Carlsmed in September 2024, most recently serving as the Company’s Senior Vice President, Operational Excellence and previously, Vice President of Advanced Manufacturin
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | Bertolini Jeffrey | -243 | - | - |
| 2026-09-30 | Bertolini Jeffrey | -243 | $13.99 | $3,400 |
| 2026-09-30 | Bertolini Jeffrey | +243 | $2.232 | $542 |
| 2026-09-08 | Bertolini Jeffrey | +50,000 | - | - |
| 2026-06-03 | Sidow Kevin | +13,698 | - | - |
| 2026-06-03 | ROOT JONATHAN D | +13,698 | - | - |
| 2026-06-03 | OBOYLE KEVIN C | +13,698 | - | - |
| 2026-06-03 | YOUNG PHILIP M | +13,698 | - | - |
| 2026-03-03 | Cordonnier Michael | -33,264 | - | - |
| 2026-03-03 | Cordonnier Michael | -160,567 | - | - |
| 2026-03-03 | Cordonnier Michael | +33,264 | $4.352 | $144,765 |
| 2026-03-03 | Cordonnier Michael | +160,567 | $0.335 | $53,790 |
| 2026-03-02 | Cordonnier Michael | -197,855 | - | - |
| 2026-03-02 | Cordonnier Michael | -197,855 | $13.292 | $2,629,889 |
| 2026-03-02 | Cordonnier Michael | +197,855 | $0.335 | $66,281 |
| 2026-01-28 | Durall William Scott | +44,977 | - | - |
| 2026-01-28 | Casey Niall | +44,977 | - | - |
| 2026-01-28 | Cordonnier Michael | +117,316 | - | - |
| 2026-01-28 | Greenstein Leonard M. | +44,977 | - | - |